Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $101.0 million.

  • X4 Pharmaceuticals' Total Non-Current Liabilities fell 603.03% to $101.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.0 million, marking a year-over-year decrease of 603.03%. This contributed to the annual value of $110.5 million for FY2024, which is 3736.14% up from last year.
  • Latest data reveals that X4 Pharmaceuticals reported Total Non-Current Liabilities of $101.0 million as of Q3 2025, which was down 603.03% from $100.7 million recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $110.5 million in Q4 2024 and a low of $49.3 million during Q1 2022
  • In the last 5 years, X4 Pharmaceuticals' Total Non-Current Liabilities had a median value of $60.0 million in 2022 and averaged $74.2 million.
  • As far as peak fluctuations go, X4 Pharmaceuticals' Total Non-Current Liabilities plummeted by 810.72% in 2022, and later surged by 8222.2% in 2024.
  • Over the past 5 years, X4 Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $51.9 million in 2021, then increased by 15.59% to $60.0 million in 2022, then surged by 34.05% to $80.5 million in 2023, then soared by 37.36% to $110.5 million in 2024, then decreased by 8.65% to $101.0 million in 2025.
  • Its last three reported values are $101.0 million in Q3 2025, $100.7 million for Q2 2025, and $104.1 million during Q1 2025.